PlainRecalls
FDA Drug Moderate Class II Ongoing

Cetrorelix Acetate for Injection, 0.25 mg, , One carton contains one packaged tray which contains: 1 vial with lyophilized powder for reconstitution, 1 pre-filled syringe with diluent, 1 20-gauge needle, 1 27-gauge needle, Sterile - For subcutaneous use only, Rx Only, Manufactured by: GP Pharm S.A. Barcelona, Spain (ESP) -08777, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs

Reported: June 7, 2023 Initiated: April 26, 2023 #D-0791-2023

Product Description

Cetrorelix Acetate for Injection, 0.25 mg, , One carton contains one packaged tray which contains: 1 vial with lyophilized powder for reconstitution, 1 pre-filled syringe with diluent, 1 20-gauge needle, 1 27-gauge needle, Sterile - For subcutaneous use only, Rx Only, Manufactured by: GP Pharm S.A. Barcelona, Spain (ESP) -08777, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs

Reason for Recall

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Details

Recalling Firm
Akorn, Inc.
Units Affected
N/A
Distribution
Nationwide in the USA and Puerto Rico
Location
Gurnee, IL

Frequently Asked Questions

What product was recalled?
Cetrorelix Acetate for Injection, 0.25 mg, , One carton contains one packaged tray which contains: 1 vial with lyophilized powder for reconstitution, 1 pre-filled syringe with diluent, 1 20-gauge needle, 1 27-gauge needle, Sterile - For subcutaneous use only, Rx Only, Manufactured by: GP Pharm S.A. Barcelona, Spain (ESP) -08777, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs. Recalled by Akorn, Inc.. Units affected: N/A.
Why was this product recalled?
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 7, 2023. Severity: Moderate. Recall number: D-0791-2023.